Effectiveness and safety of rivaroxaban therapy in daily-care patients with atrial fibrillation: Results from the Dresden NOAC registry

Thrombosis and Haemostasis

Volumn 115, Issue 5, 2016, Pages 939-949

  Hecker, Judith ^a   Marten, Sandra ^a   Keller, Loretta ^a   Helmert, Sindy ^a   Michalski, Franziska ^a   Werth, Sebastian ^a   Sahin, Kurtulus ^b   Tittl, Luise ^a   Beyer Westendorf, Jan ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b Institute for Clinical Research and Statistics   (Germany)

Author keywords

Anticoagulation; Atrial fibrillation; Bleeding; Persistence; Rivaroxaban

Indexed keywords

RIVAROXABAN; ANTICOAGULANT AGENT;

AGED; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DEATH; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EMBOLISM; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; CHEMICALLY INDUCED; COHORT ANALYSIS; COMPLICATION; GERMANY; KAPLAN MEIER METHOD; REGISTER; SAFETY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; COHORT STUDIES; EMBOLISM; FEMALE; GERMANY; HEMORRHAGE; HUMANS; ISCHEMIC ATTACK, TRANSIENT; KAPLAN-MEIER ESTIMATE; MALE; PROSPECTIVE STUDIES; REGISTRIES; RIVAROXABAN; SAFETY; STROKE; TREATMENT OUTCOME;

EID: 84964824480     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH15-10-0840     Document Type: Article

References (35)

1. Camm AJ, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33: 2719-2747.
2. Ageno W, et al. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2 Suppl): e44S-88S.
3. van Walraven C, et al. Effect of study setting on anticoagulation control: a systematic review and metaregression. Chest 2006; 129: 1155-1166.
4. Snipelisky D, Kusumoto F. Current strategies to minimize the bleeding risk of warfarin. J Blood Med 2013; 4: 89-99.
5. Heidbuchel H, et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013; 15: 625-651.
6. Patel MR, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-891.
7. Piccini JP, et al. Management of major bleeding events in patients treated with rivaroxaban vs warfarin: results from the ROCKET AF trial. Eur Heart J 2014; Epub ahead of print.
8. Beyer-Westendorf J, et al. Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry. Eur Heart J 2014; 35: 1888-1896.
9. Beyer-Westendorf J, et al. Safety of switching from Vitamin-K antagonists to dabigatran or rivaroxaban in daily care-results from the Dresden NOAC registry. Br J Clin Pharmacol 2014; Epub ahead of print.
10. Beyer-Westendorf J, et al. Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood 2014; 124: 955-962.
11. Beyer-Westendorf J, et al. Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry. Thromb Haemost 2015; 113: 1247-1257.
12. Michalski F, et al. Selection, management, and outcome of vitamin K antagonist-treated patients with atrial fibrillation not switched to novel oral anticoagulants. Results from the Dresden NOAC registry. Thromb Haemost 2015; 114: 1076-1084.
13. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3: 692-694.
14. Beyer-Westendorf J, et al. Drug persistence with rivaroxaban therapy in atrial fibrillation patients-results from the Dresden non-interventional oral anticoagulation registry. Europace 2015; Epub ahead of print.
15. Graham DJ, et al. Cardiovascular, Bleeding, and Mortality Risks in Elderly Medicare Patients Treated with Dabigatran or Warfarin for Non-Valvular Atrial Fibrillation. Circulation 2014; Epub ahead of print.
16. Sorensen R, et al. Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study. Br Med J Open 2013; 3.
17. Laliberte F, et al. Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients. Curr Med Res Opin 2014; 30: 1317-1325.
18. Tamayo S, et al. Characterizing major bleeding in patients with nonvalvular atrial fibrillation: a pharmacovigilance study of 27 467 patients taking rivaroxaban. Clin Cardiol 2015; 38: 63-68.
19. Camm AJ, et al. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J 2015; Epub ahead of print.
20. Seeger JD, et al. Safety and effectiveness of dabigatran and warfarin in routine care of patients with atrial fibrillation. Thromb Haemost 2015; 114: 1277-1289.
21. Abraham NS, et al. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study. Br Med J 2015; 350: h1857.
22. Villines TC, et al. A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system. Thromb Haemost 2015; 114: 1290-1298.
23. Avgil-Tsadok M, et al. Dabigatran use in elderly patients with atrial fibrillation. Thromb Haemost 2015; 115: Epub ahead of print.
24. Maura G, et al. Comparison of the Short-Term Risk of Bleeding and Arterial Thromboembolic Events in Nonvalvular Atrial Fibrillation Patients Newly Treated With Dabigatran or Rivaroxaban versus Vitamin K Antagonists: A French Nationwide Propensity-Matched Cohort Study. Circulation 2015; Epub ahead of print.
25. Beyth RJ, et al. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 1998; 105: 91-99.
26. Gomes T, et al. Rates of hemorrhage during warfarin therapy for atrial fibrillation. Cmaj 2013; 185: E121-127.
27. Willey VJ, et al. Management patterns and outcomes of patients with venous thromboembolism in the usual community practice setting. Clin Ther 2004; 26: 1149-1159.
28. Steffensen FH, et al. Major haemorrhagic complications during oral anticoagulant therapy in a Danish population-based cohort. J Intern Med 1997; 242: 497-503.
29. Nelson WW, et al. Medication persistence and discontinuation of rivaroxaban versus warfarin among patients with non-valvular atrial fibrillation. Curr Med Res Opin 2014; 30: 2461-2469.
30. Nelson WW, et al. Medication Persistence and Discontinuation of Rivaroxaban and Dabigatran Etexilate among Patients with Non-Valvular Atrial Fibrillation. Curr Med Res Opin 2015: 1-31.
31. Gallagher AM, et al. Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis? J Thromb Haemost 2008; 6: 1500-1506.
32. Hylek EM, et al. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007; 115: 2689-2696.
33. Fang MC, et al. Warfarin discontinuation after starting warfarin for atrial fibrillation. Circ Cardiovasc Qual Outcomes 2010; 3: 624-631.
34. Lauffenburger JC, et al. Effectiveness and safety of dabigatran and warfarin in real-world US patients with non-valvular atrial fibrillation: a retrospective cohort study. J Am Heart Assoc 2015; Epub ahead of print.
35. Larsen TB, et al. Dabigatran and warfarin for secondary prevention of stroke in atrial fibrillation patients: a nationwide cohort study. Am J Med 2014; 127: 1172-1178 e5.